Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ENTO

Entero Therapeutics Inc

Oct 22 • 04:00PM ET

4.38

+0.32 7.88 %

Healthcare • Biotechnology • USA • NASD

Peers: VNDA LGND RARE PBYI XENE CENTA CBIO PTGX PRTA

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-11.06	Insider Own	7.24%	Shs Outstand	1.59M	Perf Week	-14.29%
Market Cap	6.96M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.47M	Perf Month	-13.95%
Enterprise Value	69.48M	PEG	-	EPS next Q	-	Inst Own	2.50%	Short Float	11.74%	Perf Quarter	201.59%
Income	-17.42M	P/S	-	EPS this Y	-	Inst Trans	-1.32%	Short Ratio	0.10	Perf Half Y	303.43%
Sales	0.00M	P/B	-	EPS next Y	-	ROA	-17.88%	Short Interest	0.17M	Perf YTD	134.73%
Book/sh	-3.96	P/C	-	EPS next 5Y	-	ROE	-24.28%	52W High	5.84 -25.00%	Perf Year	97.46%
Cash/sh	0.00	P/FCF	-	EPS past 3/5Y	94.88% 82.03%	ROIC	-31.45%	52W Low	0.97 351.87%	Perf 3Y	-99.10%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	12.94% 13.36%	Perf 5Y	-100.00%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	70.78%	Oper. Margin	-	ATR (14)	0.59	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.81	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	50.18	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.81	EPS Q/Q	94.12%	SMA20	-6.21%	Beta	1.20	Target Price	108.00
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	21.35%	Rel Volume	0.07	Prev Close	4.06
Employees	2	LT Debt/Eq	0.00	Earnings	-	SMA200	122.50%	Avg Volume	1.78M	Price	4.38
IPO	Oct 11, 2016	Option/Short	No / Yes	EPS/Sales Surpr.	149.35% -	Trades		Volume	123,879	Change	7.88%

Oct-16-25 08:40AM	Entero Therapeutics, Inc., Launches Grid AI Corp to Redefine How AI Infrastructure Connects to the Power Grid (ACCESSWIRE)
Oct-14-25 11:00AM	From Biotech to Grid Tech, Entero Therapeutics Enters a $2.5 Billion Market Expected to Quadruple by 2033 (NASDAQ:ENTO) (ACCESSWIRE)
08:00AM	Entero Therapeutics Steps Into the $2.5 Billion Grid-Edge Arena With Global-Scale Validation Behind It (ACCESSWIRE)
Oct-01-25 04:05PM	ENTERO THERAPEUTICS (ENTO) Enters $100 Billion+ AI and Data Center Market with Acquisition of GRID AI (ACCESSWIRE) -14.20%
08:30AM	ENTERO THERAPEUTICS (ENTO) Acquires 100% of GRID AI, a Grid-Edge AI Platform Optimizing Next-Gen Power Demand (Newsfile)
07:24PM	Loading…
Sep-23-25 07:24PM	Entero Therapeutics, Inc. (ENTO) Names Jason D. Sawyer as New CEO Amid Strategic Shift (Insider Monkey)
Aug-14-25 09:15AM	Entero Therapeutics, Inc. Announces Reverse Stock Split (Newsfile)
Aug-11-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +66.46%
07:30AM	Entero Therapeutics, Inc. Announces $3.0 Million Private Placement Priced at the Market Under Nasdaq Rules (Newsfile)
Mar-24-25 10:51PM	Entero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC (Newsfile) -7.60%
Feb-14-25 04:00PM	Entero Therapeutics Appoints Richard Paolone as CEO (GlobeNewswire)
Feb-07-25 03:22PM	Entero Therapeutics Secures $2 Million Revolving Loan; Appoints Three New Board Members (GlobeNewswire) +8.91%
Nov-14-24 08:00AM	Entero Therapeutics CEO James Sapirstein to Moderate the 2024 BioFlorida Annual Innovation Conference CEO Forum (GlobeNewswire) -17.24%
Nov-13-24 07:00AM	Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company (GlobeNewswire)
Sep-10-24 07:00AM	Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings (GlobeNewswire)
05:00PM	Loading…
Aug-23-24 05:00PM	Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q (GlobeNewswire) +5.78%
Jul-31-24 07:00AM	Entero Therapeutics' Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program (GlobeNewswire) +6.04%
Jul-11-24 08:00AM	Entero Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds (GlobeNewswire)
Jul-09-24 07:00AM	Entero Therapeutics Announces Abstract on Celiac Disease Research Accepted for Presentation at the 20th International Celiac Disease Symposium (GlobeNewswire) +17.31%
Jun-27-24 07:34AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) -30.23%
06:00AM	Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Intestinal Damage in Celiac Disease (GlobeNewswire)
May-22-24 07:00AM	Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention (GlobeNewswire)
May-20-24 07:00AM	Entero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease Week (DDW) Conference (GlobeNewswire)
May-16-24 07:00AM	First Wave BioPharma Changes Name to Entero Therapeutics (GlobeNewswire)
May-15-24 09:52AM	FWBI Stock Earnings: First Wave BioPharma Beats EPS for Q1 2024 (InvestorPlace)
May-10-24 07:55AM	First Wave BioPharma, Inc. to raise approximately $1.1 million of Gross Proceeds Priced At-the-Market (GlobeNewswire)
May-09-24 07:00AM	First Wave BioPharma and Celiac Journey to Host Nasdaq Event in Support of Celiac Disease Awareness Month (GlobeNewswire)
Apr-29-24 09:00AM	Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV (ACCESSWIRE)
Apr-24-24 07:00AM	First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, Nutrients (GlobeNewswire)
Apr-17-24 07:00AM	First Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap Showcase (GlobeNewswire)
07:00AM	Loading…
Apr-15-24 07:00AM	First Wave BioPharma CEO James Sapirstein to Participate in 2024 Longwood Healthcare Leaders Conference (GlobeNewswire)
Apr-05-24 09:55AM	Here's Why First Wave BioPharma (FWBI) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Mar-27-24 12:00PM	First Wave BioPharma (FWBI) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-18-24 07:00AM	First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference (GlobeNewswire)
Mar-14-24 08:05AM	Why Is First Wave BioPharma (FWBI) Stock Up Today? (InvestorPlace) -17.76%
06:00AM	First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline (GlobeNewswire)
Mar-05-24 07:00AM	First Wave BioPharma to Participate In 'Fireside Chat' at the 36th Annual Roth Conference (GlobeNewswire) +11.10%
Mar-04-24 08:00AM	First Wave BioPharma, Inc. to Raise Approximately $4.0 Million of Gross Proceeds in Registered Direct Offering (GlobeNewswire) -23.92%
Feb-13-24 07:00AM	First Wave BioPharma CEO to Present at the BIO CEO & Investor Conference 2024 (GlobeNewswire) -9.11%
Jan-23-24 07:00AM	First Wave BioPharma to Present at the DealFlow MicroCap Conference (GlobeNewswire)
Jan-17-24 07:00AM	First Wave BioPharma CEO to Present at the Sequire Investor Summit 2024 in Puerto Rico (GlobeNewswire)
Jan-04-24 06:00AM	First Wave BioPharma Chairman and CEO Issues Letter to Shareholders Highlighting Recent Accomplishments and Outlook for 2024 (GlobeNewswire)
Dec-27-23 11:55AM	First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.8 Million Gross Proceeds Priced (GlobeNewswire) +49.86%
10:29AM	Why Is First Wave Biopharma (FWBI) Stock Up 148% Today? (InvestorPlace)
06:00AM	First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program (GlobeNewswire)
Dec-20-23 10:03AM	FWBI Stock Earnings: First Wave BioPharma Reported Results for Q1 2023 (InvestorPlace)
10:03AM	FWBI Stock Earnings: First Wave BioPharma Beats EPS for Q3 2023 (InvestorPlace)
Dec-18-23 06:00AM	First Wave BioPharma Announces Entry into Term Sheet for Business Combination with ImmunogenX Establishing a Leading Late-Stage GI-Focused Biopharmaceutical Company (GlobeNewswire) -22.14%
Dec-14-23 09:15AM	First Wave BioPharma Announces 1-for-20 Reverse Stock Split and Results of the Special Meeting of Stockholders (GlobeNewswire) -16.78%
Dec-06-23 07:00AM	First Wave BioPharma to Participate in BIO Partnering @JPM During J.P. Morgan Week 2024 (GlobeNewswire)
Dec-05-23 07:00AM	First Wave BioPharma CEO James Sapirstein to Moderate Panel Discussion at Longwood Healthcare Leaders Conference (GlobeNewswire)
Oct-10-23 07:00AM	Date and Time Announced for First Wave BioPharma CEO James Sapirstein's Presentation at the 2023 BIO Investor Forum (GlobeNewswire)
Oct-03-23 07:00AM	First Wave BioPharma CEO James Sapirstein to Present at the 2023 Roth Healthcare Opportunities Conference (GlobeNewswire)
Sep-15-23 08:45AM	First Wave BioPharma To Present at the BIO Investor Forum (GlobeNewswire) -13.39%
Sep-14-23 10:43AM	First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.0 Million Gross Proceeds Priced At-the-Market (GlobeNewswire) +16.75%
06:00AM	First Wave BioPharma Announces Exclusive Global License Agreement for Capeserod from Sanofi (GlobeNewswire)
Sep-05-23 07:00AM	First Wave BioPharma to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) +55.17%
Jul-19-23 08:15AM	First Wave BioPharma, Inc. Announces Pricing of $2.1 Million Public Offering (GlobeNewswire)
Jul-13-23 07:00AM	First Wave BioPharma Announces Initial Topline Results from Phase 2 SPAN Clinical Trial Investigating Enhanced Adrulipase Formulation (GlobeNewswire) -32.46%
Jul-05-23 07:00AM	First Wave BioPharma Chairman and CEO Issues Letter to Stockholders (GlobeNewswire)
Jun-28-23 07:00AM	First Wave BioPharma Announces Final Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation (GlobeNewswire)
Jun-27-23 07:00AM	First Wave BioPharma Strengthens Intellectual Property Estate (GlobeNewswire) -6.51%
Jun-15-23 11:31AM	First Wave BioPharma to Attend the 36th National Cystic Fibrosis Education Conference (July 28-30) (GlobeNewswire) +8.57%
Jun-13-23 12:50PM	First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $2.4 Million Gross Proceeds Priced At-the-Market (GlobeNewswire) +33.12%
07:00AM	First Wave BioPharma Reaches Enrollment Target for Phase 2 SPAN Adrulipase Clinical Trial in Cystic Fibrosis (GlobeNewswire)
May-15-23 07:00AM	First Wave BioPharma CEO James Sapirstein to Present at 2023 BIO International Conference (GlobeNewswire)
May-11-23 07:00AM	First Wave BioPharma Completes Patient Screening For Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis (GlobeNewswire)
May-02-23 07:30AM	First Wave BioPharma to Participate in EF Hutton Inaugural Global Conference (GlobeNewswire) -7.14%
Apr-25-23 07:00AM	First Wave Biopharma Exceeds 50% Enrollment Target for Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis (GlobeNewswire)
Mar-13-23 08:00AM	First Wave BioPharma Announces $4.0 Million Private Placement Priced At-The-Market under Nasdaq Rules (GlobeNewswire) -16.76%
07:00AM	HOOKIPA Pharma Appoints Terry Coelho to its Board of Directors (GlobeNewswire)
Mar-10-23 07:00AM	First Wave BioPharma Announces Second Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation in Cystic Fibrosis (GlobeNewswire)
Mar-09-23 07:00AM	First Wave BioPharma Announces First Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation (GlobeNewswire) +6.48%
Feb-28-23 07:00AM	First Wave BioPharma to Participate in Fireside Chat at the 35th Annual Roth Conference (GlobeNewswire)
Feb-21-23 07:00AM	First Wave BioPharma Announces Phase 2 Adrulipase Combination Trial Data to be Presented at the 2023 Digestive Disease Week (DDW) Conference (GlobeNewswire) +7.14%
Feb-13-23 07:00AM	First Wave BioPharma Chairman and CEO Issues Letter to Stockholders (GlobeNewswire) -6.30%
Feb-07-23 07:00AM	First Wave BioPharma Regains Compliance With Nasdaqs Minimum Bid Price Requirement (GlobeNewswire)
Feb-02-23 07:00AM	First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic Fibrosis (GlobeNewswire) +5.03%
Jan-31-23 07:00AM	First Wave BioPharma Announces Initiation of Phase 2 Trial Investigating Enhanced Adrulipase Formulation in Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis (GlobeNewswire) -7.51%
Jan-30-23 07:00AM	First Wave BioPharma to Present at the BIO CEO & Investor Conference (GlobeNewswire) +7.92%
Jan-25-23 07:00AM	First Wave BioPharma Announces Expansion of Adrulipase Intellectual Property Portfolio (GlobeNewswire) +22.17%
Jan-24-23 07:00AM	First Wave BioPharma to Present at Sequire Biotechnology Conference (GlobeNewswire)
Jan-13-23 04:00PM	First Wave BioPharma Provides Update on IND Filing For Phase 2 Trial of Enhanced Microgranule Formulation of Adrulipase for Exocrine Pancreatic Insufficiency (GlobeNewswire) -11.99%
10:20AM	First Wave BioPharma Announces Results of Special Meeting of Stockholders (GlobeNewswire)
Jan-09-23 09:10AM	First Wave BioPharma Announces Adjournment of Special Meeting (GlobeNewswire) -13.33%
Jan-05-23 09:45AM	ZyVersa Therapeutics Appoints Three New Board Members (PR Newswire)
Dec-12-22 07:30AM	First Wave BioPharma to Participate in BIO Partnering @ JPM During J.P. Morgan Week 2023 (GlobeNewswire)
Dec-05-22 07:00AM	First Wave BioPharma Announces Initial Clinical Sites for its Phase 2 Trial of Enhanced Microgranule Delivery Formulation of Adrulipase (GlobeNewswire)
Nov-30-22 07:00AM	First Wave BioPharma Files Investigational New Drug Application for Enhanced Microgranule Delivery Formulation of Adrulipase (GlobeNewswire) +5.60%
Nov-25-22 05:45PM	First Wave BioPharma Announces Distribution of Series F Preferred Stock to Holders of Its Common Stock (GlobeNewswire) +16.91%
Nov-22-22 04:15PM	First Wave BioPharma, Inc. Announces Closing of Private Placement (GlobeNewswire)
Nov-21-22 08:00AM	First Wave BioPharma, Inc. Announces Private Placement (GlobeNewswire) -11.61%
Nov-16-22 07:00AM	First Wave BioPharma Chairman and CEO Issues Letter to Stockholders (GlobeNewswire)
Oct-31-22 07:00AM	First Wave BioPharma Engages Rho to Manage Phase 2 Clinical Trial of Enhanced Adrulipase Formulation (GlobeNewswire)
Oct-11-22 05:30PM	First Wave BioPharma, Inc. Announces Closing of $6.0 Million Public Offering (GlobeNewswire)
Oct-10-22 07:00AM	First Wave BioPharma Presents Research Demonstrating Benefits of Improved Adrulipase Drug Delivery Formulation at AAPS 2022 PharmSci 360 (GlobeNewswire)
Oct-06-22 09:00PM	First Wave BioPharma, Inc. Announces Pricing of $6.0 Million Public Offering (GlobeNewswire) -11.96% -6.17%
08:05AM	In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews James Sapirstein CEO, First Wave BioPharma, Inc. (ACCESSWIRE)
Sep-28-22 07:00AM	First Wave BioPharmas CEO James Sapirstein to Present at Inaugural Roth Healthcare Opportunities Conference (GlobeNewswire)
Sep-19-22 07:00AM	First Wave BioPharma Chairman and CEO Issues Letter to Stockholders (GlobeNewswire) -9.25%

Entero Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its pipeline includes Latiglutenase, Capeserod, Adrulipase, and Niclosamide. The company was founded on January 30, 2014 and is headquartered in Boca Raton, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Romano Sarah	Chief Financial Officer	Jan 06 '25	Sale	0.64	727	465	17,287	Jan 08 04:23 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ENTO

Entero Therapeutics Inc

Upgrade your FINVIZ experience